Hap Trading, LLC Humanigen, Inc Call Options Transaction History

Hap Trading, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $2,370 - $47,716	-15,800 Reduced 54.3%	13,300 $0
Q2 2022 Aug 12, 2022	BUY	$1.76 - $3.33 $8,800 - $16,650	5,000 Added 20.75%	29,100 $9,000
Q1 2022 May 12, 2022	BUY	$1.81 - $3.97 $6,516 - $14,292	3,600 Added 17.56%	24,100 $18,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $1,464 - $3,288	400 Added 1.99%	20,500 $8,000
Q3 2021 Nov 10, 2021	BUY	$5.93 - $17.83 $119,193 - $358,382	20,100 New	20,100 $3,000
Q2 2021 Aug 11, 2021	SELL	$13.54 - $22.74 $850,312 - $1.43 Million	-62,800 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$12.91 - $23.83 $810,748 - $1.5 Million	62,800 New	62,800 $120,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.